Asset Acquisition (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Sep. 29, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Asset Acquisition [Line Items] | |||
| Issuance of acquisition | $ 4,718,311 | ||
| Issuance of common share | 7,006,982 | $ 3,608,555 | |
| Shares adjusted value | 4,683,099 | ||
| Unrealized gain recognized in other income | 35,212 | ||
| Value of stock issued | $ 6,714,512 | $ 3,608,555 | |
| Telomir Pharmaceuticals Inc [Member] | |||
| Asset Acquisition [Line Items] | |||
| Issuance of acquisition | 3,521,127 | ||
| Issuance of acquisition | $ 5,000,000 | ||
| Share price | $ 1.42 | ||
| SKNY Pharmaceuticals Inc [Member] | |||
| Asset Acquisition [Line Items] | |||
| Issuance of acquisition | $ 4,718,311 | ||
| Share price | $ 1.34 | ||
| Issuance of common share | $ 4,718,310 | ||
| Issuance of shares | 19,755,738 | ||
| New shares issued for value | $ 26,275,132 | ||
| Share price | $ 1.33 | ||
| Value of stock issued over net assets | $ 4,718,310 | ||
| Value of stock issued | 21,556,821 | ||
| Deemed dividend | 21,556,821 | ||
| Increase to equity of common shares | $ 4,718,311 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties. No definition available.
|
| X | ||||||||||
- Definition Amount of dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of shares of stock issued attributable to transactions classified as other. No definition available.
|
| X | ||||||||||
- Definition Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. No definition available.
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|